Pacira BioSciences, Inc. (PCRX)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 430 | 542 | 667 | 675 | 701 | 726 | 746 | 754 |
| Operating profit | $m | 33 | 18 | ||||||
| Net profit | $m | 146 | 42 | 16 | 42 | -100 | 7 | 15 | 130 |
| EPS reported | $ | 0.16 | 0.35 | ||||||
| Operating cashflow per share | $ | 3.41 | 4.76 | ||||||
| Capex per share | $ | 0.34 | 0.21 | ||||||
| FCF per share | $ | 3.07 | 4.55 | ||||||
| Free cash flow | $m | 137 | 180 | ||||||
| Net debt | $m | 180 | 151 | ||||||
| Book value equity | $m | 693 | 672 | ||||||
| Book value per share | $ | 15.39 | 16.67 | ||||||
| Number of shares | m | 45.04 | 40.3 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 161.75 | 71.51 | ||||||
| P/B LTM | x | 1.66 | 1.72 | ||||||
| P/S LTM | x | 1.59 | 1.55 | ||||||
| P/FCF LTM | x | 8.44 | 6.42 | ||||||
| EV/EBITDA LTM | x | 11.83 | 12.63 | ||||||
| EV/Sales LTM | x | 2.00 | 1.49 | ||||||
| Earnings Yield LTM | % | +0.62% | +1.40% | ||||||
| FCF Yield | % | +11.85% | +15.56% | ||||||
| Quality | |||||||||
| ROE | % | +1.01% | +2.13% | ||||||
| ROIC | % | +1.20% | +1.35% | ||||||
| Operating margin | % | +4.58% | +2.47% | ||||||
| Gross margin | % | +79.39% | +79.21% | ||||||
| FCF/Sales | % | +18.81% | +24.06% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | +3.63% | +6.45% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | -23.55% | +0.43% | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | 0.30 | 0.44 | ||||||
| Net Debt/EBITDA | x | 2.41 | 1.80 | ||||||
| EBIT/Net interest | x | 2.28 | 1.33 | ||||||
| Net debt/market cap | % | +36.26% | +41.28% | ||||||
| Net debt/Equity | x | 0.26 | 0.22 | ||||||
| Gross debt/equity | x | 0.66 | 0.61 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Operating within the United States, Pacira BioSciences, Inc. is dedicated to providing healthcare professionals and their patients with non-opioid solutions for pain management and regenerative health. Its offerings include EXPAREL, an injectable liposomal bupivacaine suspension, and ZILRETTA, an extended-release injectable suspension of triamcinolone acetonide. Furthermore, the company offers the iovera system, a non-opioid, handheld cryoanalgesia device capable of delivering precisely controlled cold temperatures to targeted nerves. Pacira also develops its unique multivesicular liposome (MVL) drug delivery technology, which encapsulates therapeutic compounds while preserving their inherent molecular structure. Established in 2006, the firm was formerly known as Pacira Pharmaceuticals, Inc. until its name change to Pacira BioSciences, Inc. in April 2019. Its main corporate office is situated in Tampa, Florida.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Operating within the United States, Pacira BioSciences, Inc. is dedicated to providing healthcare professionals and their patients with non-opioid solutions for pain management and regenerative health. Its offerings include EXPAREL, an injectable liposomal bupivacaine suspension, and ZILRETTA, an extended-release injectable suspension of triamcinolone acetonide. Furthermore, the company offers the iovera system, a non-opioid, handheld cryoanalgesia device capable of delivering precisely controlled cold temperatures to targeted nerves. Pacira also develops its unique multivesicular liposome (MVL) drug delivery technology, which encapsulates therapeutic compounds while preserving their inherent molecular structure. Established in 2006, the firm was formerly known as Pacira Pharmaceuticals, Inc. until its name change to Pacira BioSciences, Inc. in April 2019. Its main corporate office is situated in Tampa, Florida.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free